Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
about
Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathwayAnalysis of the genome to personalize therapy for melanomaTherapeutic Implications of Targeting AKT Signaling in MelanomaMelanoma: oncogenic drivers and the immune systemMelanoma: new insights and new therapiesInnate and adaptive immune cells in the tumor microenvironmentPTEN: one gene, many syndromesOncogenic mutations of PIK3CA in human cancersNuclear PTEN levels and G2 progression in melanoma cellsCombined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in ChordomaExosome-mediated delivery of the intrinsic C-terminus domain of PTEN protects it from proteasomal degradation and ablates tumorigenesisSynthetic lethality: emerging targets and opportunities in melanoma.Dormancy of metastatic melanomaMolecular pathogenesis of sporadic melanoma and melanoma-initiating cells.Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanomaGermline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults.Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy.Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo.Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in miceEpigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanomaPTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck.Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.Complete loss of PTEN protein expression correlates with shorter time to brain metastasis and survival in stage IIIB/C melanoma patients with BRAFV600 mutationsFunctional modulation of IGF-binding protein-3 expression in melanomaThe antiproliferative response of indole-3-carbinol in human melanoma cells is triggered by an interaction with NEDD4-1 and disruption of wild-type PTEN degradationTargeted therapy for melanoma: a primer.Driver mutations in melanoma: lessons learned from bench-to-bedside studiesCross signaling, cell specificity, and physiology.Odontogenic ameloblast-associated protein (ODAM) inhibits growth and migration of human melanoma cells and elicits PTEN elevation and inactivation of PI3K/AKT signaling.Nf-kappa B, chemokine gene transcription and tumour growthNew horizons in melanoma treatment: targeting molecular pathways.Negative Regulation of Receptor Tyrosine Kinase (RTK) Signaling: A Developing FieldPTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers.Considerations when analyzing the methylation status of PTEN tumor suppressor gene.Targeted agents for the treatment of metastatic melanoma.Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.Functional and therapeutic significance of Akt deregulation in malignant melanoma.Role of nuclear factor-kappa B in melanoma.NF-kappaB activation in melanoma.The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation
P2860
Q24532136-7E70B923-2A64-4040-82EC-EDA5B0E5DF8EQ24601008-2198026B-47C3-4C96-B12D-E2B7E8EDE43AQ24631438-398357DA-79DD-4987-8E28-6AB94940C4E9Q26775598-F69A8888-7BC7-482C-8F3B-8EA7F6927BE6Q26853127-3E2A7819-9BBD-40AD-91E5-0F930F7C6100Q27008342-6A7DD5FA-52B0-4F9D-91DD-A6BF90812981Q28203387-9913FA44-23BE-4DC6-937E-C38467B05894Q28284802-1B86D6FD-628C-4536-9C78-412231A8E3FEQ28391204-29A64534-F130-453C-B4BE-DE135758FBA1Q30278895-772912DE-EBEC-4410-AE62-3E55D3E77552Q30392471-E25F4418-8E86-4731-A125-D7389FBEE0F9Q33578398-F359B9E9-E703-4320-9637-8D21E1FB351EQ33649569-2F3B272F-06E8-4191-B2EB-0CB57B676BE8Q33725172-D6D856B8-A177-4D72-8068-CB8142B99FDEQ33790743-55BE5B2F-B538-40D2-BC86-6862DB63ED28Q33905657-94986BA9-81F4-4632-AC7E-C754E5CB402BQ33917630-8B40932D-F8F2-4AE4-B614-0E8662AC01A1Q33942901-15F647C5-7004-4C3C-BEE0-BBE72D1D04E4Q34009762-2F01F6C1-48E5-4D92-8E2B-CD274781E34DQ34031613-12DD59A3-F2A4-4632-BA45-3FC431C9E859Q34193836-5F79F0DB-B825-4649-9DEA-6F081A738618Q34253185-25E0F860-0A13-4F6C-A42C-9D1A9423BC4AQ34438555-BD83E40D-94A5-48ED-8466-CC7C641680D7Q34505279-32EC4F48-C376-4DB7-AE01-4B7EB9918861Q34518472-CCE1D5F1-1FC9-4FC4-BA2F-E1DE89E7C4A5Q34540273-D71AEE01-9199-444E-BC3D-1CE804E34905Q34639532-672463F0-0120-477E-81E4-73203EA0E797Q34675896-80E4B977-2F0C-4047-A9BA-9E910E5239DDQ34707834-FEB54699-79D6-4530-9BC4-9702FA5176BCQ34810265-506A9861-1826-451E-9ADD-1AF7C0F935F1Q34986188-D449B6B7-E7F0-4634-B21A-E61C1A4474DDQ34996130-52C0486F-8758-40D9-9D3A-4639A81CC2EBQ35747653-2376666F-378E-49C8-917C-50EB3E14F642Q35788734-85CF274B-C0E2-4938-A4D7-1BB33B202EF8Q35822194-429EBFF1-9831-450E-A52C-E5C828BE9D3DQ35842249-5B8D0221-022E-4D9F-8A03-02739C6142AFQ36178371-4FDE1F60-4F91-4C9C-8155-B627DD1763A0Q36178379-A56B6582-9D93-4E44-851A-8E244F075F48Q36416479-4FAC06BE-0E76-4030-A6D9-8D24F441C739Q36476282-E8BA6F6E-6CE8-4742-AB9D-2F32D09D3D9B
P2860
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
@ast
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
@en
type
label
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
@ast
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
@en
prefLabel
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
@ast
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
@en
P2093
P2860
P1476
Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.
@en
P2093
P2860
P304
P356
10.1016/S0002-9440(10)64627-5
P407
P577
2000-10-01T00:00:00Z